Exelixis Inc Restructuring Reserve, Current
Exelixis Inc (EXEL) had Restructuring Reserve, Current of $3.02 million as of 2016-03-31, per its 10-Q filed 2016-05-04.
Discontinued › Notes › Restructuring and Related Activities
us-gaap:RestructuringReserveCurrent · last filed 2016-05-04
- 2016-03-31: Restructuring Reserve, Current $3.02M.
- 2015-12-31: Restructuring Reserve, Current $3.21M.
- 2015-09-30: Restructuring Reserve, Current $3.73M.
- 2015-06-30: Restructuring Reserve, Current $5.29M.
| Period end | Restructuring Reserve, Current |
|---|---|
| 2016-03-31 | $3.02M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $3.21M 10-Q · filed 2016-05-04 |
| 2015-09-30 | $3.73M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $5.29M 10-Q · filed 2015-08-11 |
| 2015-03-31 | $4.99M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $6.43M 10-K · filed 2016-02-29 |
| 2014-09-30 | $6.58M 10-Q · filed 2014-11-04 |
| 2014-06-30 | $3.73M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $4.30M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $4.42M 10-K · filed 2015-03-02 |
| 2013-09-30 | $3.78M 10-Q · filed 2013-10-30 |
| 2013-06-30 | $4.19M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $4.08M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $5.08M 10-K · filed 2014-02-20 |
| 2012-09-30 | $4.03M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $4.48M 10-Q · filed 2012-08-02 |
| 2011-12-31 | $4.48M 10-K · filed 2013-02-21 |
| 2011-09-30 | $2.73M 10-Q · filed 2011-10-27 |
| 2011-06-30 | $2.62M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $7.29M 10-Q · filed 2011-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |